Updates on the Treatment of Erythrodermic Psoriasis
Yang Lo,1 Tsen-Fang Tsai2 1Department of Dermatology, Cathay General Hospital, Taipei, Taiwan; 2Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, TaiwanCorrespondence: Tsen-Fang Tsai Tel +886-2-2312-3456 #65734Email tftsai@yaho...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/4e0ce0bf5c1d451dabbbe4bb6971c1c9 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Yang Lo,1 Tsen-Fang Tsai2 1Department of Dermatology, Cathay General Hospital, Taipei, Taiwan; 2Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, TaiwanCorrespondence: Tsen-Fang Tsai Tel +886-2-2312-3456 #65734Email tftsai@yahoo.comAbstract: Erythrodermic psoriasis (EP) is a rare variant of psoriasis, which is potentially life threatening and often resistant to conventional therapy. Biologics have revolutionized the treatment of plaque-type psoriasis, and shown promise in EP. However, due to the lack of head-to-head studies and the rarity of EP, no high level evidence-based treatment guidelines for EP have been established, and the evidence of treatment of EP is limited to case reports or small case series. Here, we present a narrative review focusing on the up-to-date information for the treatment of EP.Keywords: erythrodermic psoriasis, treatment |
|---|